Univ.-Prof. PD Mag pharm Dr Markus Mitterhauser, aHPhHead of Experimental Nuclear Medicine, Director Ludwig Boltzmann Institute Applied Diagnostics
Department of Biomedical Imaging and Image-guided Therapy (Division of Nuclear Medicine)
Position: Professor
ORCID: 0000-0003-3173-5272
T +43 1 06767620420
markus.mitterhauser@meduniwien.ac.at
Keywords
Molecular Imaging; Nuclear Medicine; Radionuclide Imaging
Research group(s)
- Joint Medicinal Applied Radiochemistry Facility
Head: Markus Mitterhauser
Research Area: The newly founded Joint Applied Medicinal Radiochemistry Facility of the University of Vienna and the Medical University of Vienna connects researchers from different disciplines of the University of Vienna and the Medical University Vienna ranging from basic science to clinical applications.
Members: - Ludwig Boltzmann Institute Applied Diagnostics
Research Area: The focus of the institute lies on the development of non-invasive diagnostic methods linking molecular epigenetic and genetic signatures with molecular imaging biomarkers for PET and SPECT analysis. The combination of these two methods will allow for improved functional, spatial and temporal assessment of tumor load and molecular tumor characterization.
Members:
Research interests
My main research focus is experimental Nuclear Medicine: the development and validation of molecular probes for diagnosis and therapy stratification.
Techniques, methods & infrastructure
- preclinical imaging lab (PIL)
- nuclear medicine Biolabs
- Radiopharmacy
Grants
- new preclinical models for tracer development (2020)
Source of Funding: FFG (Austrian Research Promotion Agency), industrienahe Dissertationen
Principal Investigator - Patient involvment in Oncology (2020)
Source of Funding: LBG (Ludwig Boltzmann Gesellschaft), PPIE
Principal Investigator - Dual Isotope Imaging (2019)
Source of Funding: FFG (Austrian Research Promotion Agency), Industrienahe Dissertationen
Principal Investigator - LBI Applied Diagnostics (2015)
Source of Funding: LBG (Ludwig Boltzmann Gesellschaft), Institute Call
Principal Investigator - Der Adenosin A3 Rezeptor als neues Target für die onkologische Bildgebung mit PET (2014)
Source of Funding: FWF (Austrian Science Fund), Stand-Alone Projects
Principal Investigator - Simultaneous PET-MRI of the prostate for improved diagnosis and advanced radiotherapy treatment (2011)
Source of Funding: Medical University of Vienna, CCC RCG011
Principal Investigator - “[11C]DASB and ADHS (2009)
Source of Funding: OeNB (Oesterreichische Nationalbank), Anniversary Fund
Principal Investigator - Evaluierung von [18F]FE@SNAP und [11C]SNAP-7941 als Liganden für den MCH1 Rezeptor (2008)
Source of Funding: FWF (Austrian Science Fund), Stand-Alone Projects
Principal Investigator - Evaluierung von (18F)FE@SUPPY als Ligand für den A3 Rezeptor (2006)
Source of Funding: FWF (Austrian Science Fund), Stand-Alone Projects
Principal Investigator - Preclinical Evaluation of [18F]FE@CIT (2005)
Source of Funding: OeNB (Oesterreichische Nationalbank), Anniversary Fund
Principal Investigator